Efficacy and effect of free treatment on multidrug‑resistant tuberculosis

Zhang,Qing; Wu,Zheyuan; Zhang,Zurong; Sha,Wei; Shen,Xin; Xiao,Heping

doi:10.3892/etm.2015.2966

Efficacy and effect of free treatment on multidrug‑resistant tuberculosis

Authors:
- Qing Zhang
- Zheyuan Wu
- Zurong Zhang
- Wei Sha
- Xin Shen
- Heping Xiao
View Affiliations

Affiliations: Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China, Shanghai Center for Disease Control and Prevention, Shanghai 200065, P.R. China
Published online on: December 29, 2015 https://doi.org/10.3892/etm.2015.2966
Pages: 777-782
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug‑resistant tuberculosis (MDR‑TB) is a serious public health and social issue. It pertains to the type of tuberculosis that is resistant simultaneously to isoniazid and rifampicin. MDR‑TB has a high mortality and is expensive to treat. The aim of the present study was to examine the therapeutic effects of individualized free treatment and the relevant influencing factors on the treatment outcome for MDR‑TB. A prospective study module was used to analyze the therapeutic outcome of MDR‑TB with individualized free treatment for 160 patients between 2011 and 2014. Statistical analysis was performed using the Chi‑square or Fisher's exact test, and the odds ratio was calculated using a logistic regression analysis model. In total, 160 patients were enrolled in the study for treatment of MDR‑TB. From these, 88 cases completed the course of treatment, and 70 cases were successfully treated. Of the remaining 72 cases, 37 cases exhibited treatment failure, 18 cases were suspended during treatment and 17 patients succumbed to the disease. The results showed that the confounding factors were: i) retreatment (p<0.05); ii) occurrence of diabetes (p<0.001); iii) lesion without improvement in radiography during treatment (p=0.001); iv) positive sputum culture for Mycobacterium tuberculosis after 3‑month treatment (p<0.05); and v) termination of treatment due to adverse reaction (p<0.05). These factors were associated with poor treatment outcomes by logistic regression analysis. Adverse drug reaction was observed in 33 cases and treatment was terminated or changed permanently in 29 of these cases. The most common adverse reaction was liver function damage caused by pyrazinamide and leucopenia caused by rifabutin. One patient suffered from serious liver failure. In conclusion, the success rate of long treatment course for MDR‑TB is not high due to many adverse reactions. Occurrence of diabetes is the main factor that caused poor efficacy.

View Figures

View References

1	World Health Organization (WHO): Multidrug-resistant tuberculosis (MDR-TB): 2013 Update. WHO, Geneva, Switzerland: 2013.
2	Laniado-Laborín R: Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered. Expert Rev Respir Med. 4:143–146. 2010. View Article : Google Scholar : PubMed/NCBI
3	World Health Organization (WHO): Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. WHO (Geneva, Switzerland). 2011.
4	World Health Organization (WHO): Definitions and reporting framework for tuberculosis - 2013 revision. WHO (Geneva, Switzerland). 2013.
5	World Health Organization (WHO): Global tuberculosis report 2013. WHO (Geneva, Switzerland). 2013.
6	Bastos ML, Hussain H, Weyer K, et al: Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 59:1364–1374. 2014. View Article : Google Scholar : PubMed/NCBI
7	World Health Organization (WHO): Global tuberculosis control report 2011. WHO (Geneva, Switzerland). 2011.
8	Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR and Galvani AP: Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis. 9:153–161. 2009. View Article : Google Scholar : PubMed/NCBI
9	Mitnick CD, Franke MF, Rich ML, Viru Alcantara FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HS, et al: Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 8:e586642013. View Article : Google Scholar : PubMed/NCBI
10	Rodriguez M, Monedero I, Caminero JA, et al: Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 17:520–525. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kliiman K and Altraja A: Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 33:1085–1094. 2009. View Article : Google Scholar : PubMed/NCBI
12	Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B and Woo PC: Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One. 6:e193992011. View Article : Google Scholar : PubMed/NCBI
13	Jain K, Desai M, Solanki R and Dikshit RK: Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 5:145–149. 2014. View Article : Google Scholar : PubMed/NCBI
14	Marais E, Mlambo CK, Lewis JJ, Rastogi N, Zozio T, Grobusch MP, Duse A, Victor T and Warren RW: Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa. Infection. 42:405–413. 2014. View Article : Google Scholar : PubMed/NCBI
15	Brust JC, Gandhi NR, Carrara H, Osburn G and Padayatchi N: High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000–2003. Int J Tuberc Lung Dis. 14:413–419. 2010.PubMed/NCBI
16	Qazi F, Khan U, Khowaja S, Javaid M, Ahmed A, Salahuddin N, Hussain H, Becerra MC, Golub JE and Khan AJ: Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis. 15:1556–1559, i. 2011. View Article : Google Scholar : PubMed/NCBI
17	Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, et al: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 360:2397–2405. 2009. View Article : Google Scholar : PubMed/NCBI
18	Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, Puri MM, Visalakshi P and Behera D: Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 13:976–981. 2009.PubMed/NCBI
19	Prasad R, Verma SK, Sahai S, Kumar S and Jain A: Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci. 48:183–186. 2006.PubMed/NCBI
20	Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, et al: Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 92:397–403. 2012. View Article : Google Scholar : PubMed/NCBI
21	Falzon D, Gandhi N, Migliori GB, et al: Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB: Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 42:156–168. 2013. View Article : Google Scholar : PubMed/NCBI
22	Johnston JC, Shahidi NC, Sadatsafavi M and Fitzgerald JM: Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 4:e69142009. View Article : Google Scholar : PubMed/NCBI
23	Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, Karimovich HA, Kebede Y and Mills C: Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One. 2:e11262007. View Article : Google Scholar : PubMed/NCBI